Medicines for Europe regularly seeks for dynamic and committed professionals who want to contribute to better access to medicines, and better health for European citizens and beyond.
If you are looking for a new challenge, do not hesitate to apply.
If there are no open vacancies or if the vacancies available do not match your profile, make sure you follow us on social media LinkedIn and Twitter to be notified of future vacancies.
You can also send spontaneous applications to info@medicinesforeurope.com.
We will consider spontaneous applications once opportunities arise.
We are grateful for your interest in joining our Medicines for Europe Team.
The European Union and the United States are each other’s main trading partners for medicinal and pharmaceutical products, which are the EU’s most significant exports to the US and the second most significant US exports to the EU.
The Biosimilar Market Access Committee (Biosimilar medicines Group, a Medicines for Europe sector group) undertook a 2023 Biosimilar market review consisting of updates on biosimilar medicines policy across Europe (28 European countries).
The highlights of this overview have been consolidated below and illustrate both key challenges and recommendations on how to improve specific policy interventions (e.g. pricing and reimbursement, procurement, prescribing and dispensing) to enhance biosimilar medicines use and competition in the biologics market in Europe.